Est. 2001·3,000+ placements · six offices · four regions

Company signals · Biotech & Pharma

ACROBiosystems

1 signal in the current window, with MitchelLake's leadership read on each.

Last updated

Market context: This lands while the Talent Market Index reads 97.8 (Neutral) — down 3.2 versus the prior month — and Americas signal share is easing (-15.7pts).

ACROBiosystems: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 34 tracked companies.

Signals at ACROBiosystems

ACROBiosystems signals in the last 90 days

1 public signal observed since 13 August 2026, by type.

More signals across Biotech & Pharma

Product Launch · Americas

ABEC →

ABEC announced the commercial launch of the ATB-2100 Advanced Therapy Bioreactor, a single-use cell expansion platform aimed at advanced therapy (cell and gene therapy) manufacturing.

Product Launch · Americas

Thermo Fisher Scientific →

Thermo Fisher Scientific launched Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin-free basal and feed media in liquid and dry powder formats for CHO-K1 cell line support in biologics and biosimilars production.

Product Launch · Americas

DBV Technologies →

DBV Technologies submitted a Biologics License Application to the U.S. FDA for VIASKIN® Peanut Patch for children aged 4-7 years, advancing its immunotherapy product through regulatory pathway.

Product Launch · Americas

Teva Pharmaceutical Industries Ltd. →

Teva received U.S. FDA approval for DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab), for treatment of bone complications in advanced cancer patients, giant cell tumor of bone, and hypercalcemia of malignancy.

Product Launch · Americas

Bristol Myers Squibb →

FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.

Product Launch · Americas

Amgen →

Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.

Where ACROBiosystems's market lands in our work

Weekly briefing

Track companies like ACROBiosystems — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record

MitchelLake is a global executive search and advisory firm covering AI, innovation and expansion leadership for companies navigating transformation and change across industries, from startups and scale-ups to private-equity-backed and enterprise organisations. 3,000+ C-suite, specialist and board placements since 2001.

Data period
24 Sept 2026 – 24 Sept 2026 · 1 signals for this company
Publisher
MitchelLake

Last updated